NEW YORK, Sept. 15, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies Inc. (Nasdaq:SIGA) announced that its smallpox antiviral drug, ST-246, has been used to treat a Pennsylvania patient suffering from complications due to exposure to a live vaccinia-vectored rabies vaccine. Following consultation with the Pennsylvania Health Department, the Centers for Disease Control and Prevention, and the Food and Drug Administration, an eIND (Emergency Investigational New Drug) was approved to permit the use of ST-246, an investigational drug, in the patient. After a single 14-day course of oral ST-246 therapy (2 capsules once per day), together with vaccinia immunoglobulin (VIG), the infection was resolved and the patient was discharged from the hospital.
